Navigation Links
Amarantus Completes Name Change and CUSIP Change
Date:12/3/2012

SUNNYVALE, Calif., Dec. 3, 2012 /PRNewswire/ -- Amarantus Bioscience, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has completed a name change from Amarantus Biosciences, Inc. to Amarantus Bioscience, Inc. In conjunction with this announcement, the Company has received a new Committee on Uniform Securities Identification Procedures (CUSIP) number of 02300T109. The Company's International Securities Identification Number has also changed to US02300T1097. These changes are part of an ongoing effort to improve the regularity of trading in the Company's common stock. These changes will have no impact on the marketability of the Company's securities, or the ability to trade the common stock through brokerage firms.

The Company believes that its fundamentals remain strong and is looking forward to continuing to update the marketplace regarding developments on an ongoing basis. The Company has not entered into any financing transactions that would cause shareholder dilution since the Company's 10Q was reported on November 19th, 2012. The Company has not sold any shares into the marketplace. None of the officers or directors of the Company have sold any shares into the marketplace. The officers and directors of the corporation continue to believe in the Company and its fundamentals.

About Amarantus Bioscience, Inc.

Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. This press release does not represent an offer to buy or sell securities.

Amarantus Bioscience, Inc.
(408) 737-2734
pr@amarantus.com

Investor/Media Contact:
IR Sense, LLC
Remy Bernarda
415-203-6386
remy@irsense.com


'/>"/>
SOURCE Amarantus Bioscience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
2. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
3. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
6. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
7. Amarantus BioSciences Secures $1.1 Million in Financing
8. Amarantus BioSciences Issues CEO Letter to Shareholders
9. Amarantus BioSciences Wins MANF Patent Challenge in Europe
10. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
11. Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 01, 2016 , ... ... tube systems for North American hospitals, will present its chain-of-custody solution for tracking ... Exhibition in Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven ...
(Date:12/2/2016)... Washington, DC (PRWEB) , ... ... ... Technologies Consortiumâ„¢ (ETC), a consortium of pharmaceutical and biotechnology companies dedicated to ... is seeking companies interested in supplying a vendor-supported, portable online UHPLC, with ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... magnet Voice Coil Actuator with a flexure design that ensures high alignment accuracy ... cost-effective pricing and is ideally suited where extreme precision is required, such as ...
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
Breaking Biology News(10 mins):